NEW YORK (GenomeWeb) – MolecularMatch and Liquid Biotech USA plan to partner to develop liquid biopsy technology for cancer, the companies said today.
As part of the partnership, Liquid Biotech, which is developing proprietary circulating tumor cell detection technology, will use MolecularMatch's database to correlate genomic test results with treatments. MolecularMatch, which was founded in 2014, has developed software to match the genetic profile of cancer patients' tumors to clinical trials and available drugs.
MoelcularMatch CEO Kevin Coker said in a statement that the partnership would help bridge the gap between liquid biopsy testing and the "resource-consuming matter of tracking innumerable treatments and trial data."
Liquid Biotech Chairman and CEO Phillip Sass added in the statement that the main advantage of his firm's test is in "early, precision detection," and that MolecularMatch's technology would complement its test by matching the results to available treatment and clinical trials, adding speed.
Liquid Biotech spun out of the University of Pennsylvania and raised $2 million last December to further develop its proprietary circulating tumor cell identification and isolation technology.